Login Register Cart 0
Generic placeholder image

Current Biotechnology

Editor-in-Chief

ISSN (Print): 2211-5501
ISSN (Online): 2211-551X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Exposure to Endocrine-disrupting Chemicals and Environmental Toxins Attributing to Polycystic Ovarian Syndrome

Author(s): Subrata Mandal, Rukaiah Fatma Begum, Chitra Vellapandian and Sumithra Mohan*

Volume 13, Issue 1, 2024

Published on: 04 January, 2024

Page: [15 - 25] Pages: 11

DOI: 10.2174/0122115501283971231226112856

Price: $65

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrinopathy characterized by excess androgen and infertility due to anovulatory failure. A significant fraction of the world's population is affected by the infertility condition known as PCOS. Due to the disease's complicated nature and overlapping symptoms, diagnosis of the condition is frequently challenging. Exogenous compounds or combinations known as endocrine-disrupting chemicals (EDCs) can imitate the effects of steroid hormones and obstruct their metabolism. EDCs and this condition have recently been the subject of intensive research to better understand the possible contribution of these substances to the pathophysiology of PCOS. It was shown that EDC exposure can be connected to PCOS in either a direct or indirect way since PCOS is linked to higher levels of oxidative stress and inflammation, which lead to obesity, insulin resistance, and infertility. This review's objective is to investigate how exposure to environmental contaminants affects the etiology of polycystic ovarian syndrome.

Keywords: Endocrine-Disrupting Chemicals (EDCs), Polycystic ovarian syndrome (PCOS), Infertility, Bisphenol A, Phthalates, Persistent organic pollutants (POPs).

« Previous Next »
Graphical Abstract

[1]
Sam S, Dunaif A. Polycystic ovary syndrome: Syndrome XX? Trends Endocrinol Metab 2003; 14(8): 365-70.
[http://dx.doi.org/10.1016/j.tem.2003.08.002] [PMID: 14516934]
[2]
Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: Searching for the way out of the labyrinth. Hum Reprod Update 2005; 11(6): 631-43.
[http://dx.doi.org/10.1093/humupd/dmi025] [PMID: 15994846]
[3]
Franks S, McCarthy M, Hardy K. Development of polycystic ovary syndrome: Involvement of genetic and environmental factors. Int J Androl 2006; 29(1): 278-85.
[http://dx.doi.org/10.1111/j.1365-2605.2005.00623.x ] [PMID: 16390494]
[4]
Diamanti-Kandarakis E, Piperi C, Argyrakopoulou G, et al. Polycystic ovary syndrome: The influence of environmental and genetic factors. Hormones 2006; 5(1): 17-34.
[http://dx.doi.org/10.14310/horm.2002.11165] [PMID: 16728382]
[5]
Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine-disrupting chemicals: An Endocrine Society scientific statement. Endocr Rev 2009; 30(4): 293-342.
[http://dx.doi.org/10.1210/er.2009-0002] [PMID: 19502515]
[6]
Rutkowska AZ, Diamanti-Kandarakis E. Polycystic ovary syndrome and environmental toxins. Fertil Steril 2016; 106(4): 948-58.
[http://dx.doi.org/10.1016/j.fertnstert.2016.08.031] [PMID: 27559705]
[7]
ACOG committee opinion no 575. Exposure to toxic environmental agents. Fertil Steril 2013; 100(4): 931-4.
[http://dx.doi.org/10.1016/j.fertnstert.2013.08.043]
[8]
Merkin SS, Phy JL, Sites CK, Yang D. Environmental determinants of polycystic ovary syndrome. Fertil Steril 2016; 106(1): 16-24.
[http://dx.doi.org/10.1016/j.fertnstert.2016.05.011]
[9]
Patisaul H, Adewale HB. Long-term effects of environmental endocrine disruptors on reproductive physiology and behavior. Front Behav Neurosci 2009; 3(JUN): 10.
[http://dx.doi.org/10.3389/neuro.08.010.2009] [PMID: 19587848]
[10]
Boekelheide K, Blumberg B, Chapin RE, et al. Predicting later-life outcomes of early-life exposures. Environ Health Perspect 2012; 120(10): 1353-61.
[http://dx.doi.org/10.1289/ehp.1204934] [PMID: 22672778]
[11]
Sadeghi HM, Adeli I, Calina D, et al. Polycystic ovary syndrome: A comprehensive review of pathogenesis, management, and drug repurposing. Int J Mol Sci 2022; 23(2): 583.
[http://dx.doi.org/10.3390/ijms23020583] [PMID: 35054768]
[12]
Calina D, Oana Docea A, Golokhvast KS, Sifakis S, Tsatsakis A, Makrigiannakis A. Management of endocrinopathies in pregnancy: A review of current evidence. Int J Environ Res Public Health 2019; 16(5): 781.
[http://dx.doi.org/10.3390/ijerph16050781]
[13]
Fernández B, Lobo L, Pereiro R. Encyclopedia of Analytical Science: Atomic Absorption Spectrometry: Fundamentals. Instrumentation and Capabilities 2019; pp. 137-43.
[14]
Soave I, Occhiali T, Assorgi C, Marci R, Caserta D. Environmental toxin exposure in polycystic ovary syndrome women and possible ovarian neoplastic repercussion. Curr Med Res Opin 2020; 36(4): 693-703.
[http://dx.doi.org/10.1080/03007995.2020.1729108]
[15]
Palioura E, Diamanti-Kandarakis E. Polycystic ovary syndrome (PCOS) and endocrine disrupting chemicals (EDCs). Rev Endocr Metab Disord 2016; 16(4): 365-71.
[http://dx.doi.org/10.1007/s11154-016-9326-7]
[16]
Palioura E, Diamanti-Kandarakis E. Sci-Hub | Industrial endocrine disruptors and polycystic ovary syndrome. J Endocrinol Invest 2013; 36(11): 1105-11.
[17]
Sobolewski M, Barrett E. Polycystic ovary syndrome: Do endocrine-disrupting chemicals play a role? Semin Reprod Med 2014; 32(3): 166-76.
[http://dx.doi.org/10.1055/s-0034-1371088] [PMID: 24715511]
[18]
Victor VM, Rocha M, Bañuls C, et al. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab 2011; 96(10): 3115-22.
[http://dx.doi.org/10.1210/jc.2011-0651] [PMID: 21778215]
[19]
Zhang B, Zhou W, Shi Y, Zhang J, Cui L, Chen ZJ. Lifestyle and environmental contributions to ovulatory dysfunction in women of polycystic ovary syndrome. BMC Endocr Disord 2020; 20(1): 19.
[http://dx.doi.org/10.1186/s12902-020-0497-6] [PMID: 32000752]
[20]
Yang Q, Zhao Y, Qiu X, Zhang C, Li R, Qiao J. National natural science foundation of china (21322705, 21190051, 41121004 and 81170538), national key technology r&d program in the twelve five-year plan. Hum Reprod 2012; 30(8): 1964-73.
[http://dx.doi.org/10.1093/humrep/dev123] [PMID: 26040477]
[21]
Nilsson E, Klukovich R, Sadler-Riggleman I, et al. Environmental toxicant induced epigenetic transgenerational inheritance of ovarian pathology and granulosa cell epigenome and transcriptome alterations: Ancestral origins of polycystic ovarian syndrome and primary ovarian insufficiency. Epigenetics 2018; 13(8): 875-95.
[http://dx.doi.org/10.1080/15592294.2018.1521223 ] [PMID: 30207508]
[22]
Mimouni NEH, Paiva I, Barbotin A-L, et al. Polycystic ovary syndrome is transmitted via a transgenerational epigenetic process. Cell Metab 2021; 33(3): 513-530.e8.
[http://dx.doi.org/10.1016/j.cmet.2021.01.004]
[23]
Singh S, et al. Polycystic ovary syndrome: Etiology, current management, and future therapeutics. J Clin Med 2023; 12(4): 1454.
[http://dx.doi.org/10.3390/jcm12041454]
[24]
Teede HJ, Misso ML, Costello MF, et al. International PCOS network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.In:Fertil Steril. 2018; 110: pp. (3)364-79.
[http://dx.doi.org/10.1016/j.fertnstert.2018.05.004]
[25]
Ujvari D, Hulchiy M, Calaby A, Nybacka A, Byström B, Hirschberg AL. Lifestyle intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of overweight/obese women with polycystic ovary syndrome. Hum Reprod 2014; 29(7): 1526-35.
[http://dx.doi.org/10.1093/humrep/deu114] [PMID: 24842895]
[26]
Kazemi M, Hadi A, Pierson RA, Lujan ME, Zello GA, Chilibeck PD. Effects of dietary glycemic index and glycemic load on cardiometabolic and reproductive profiles in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Adv Nutr 2021; 12(1): 161-78.
[http://dx.doi.org/10.1093/advances/nmaa092]
[27]
Szczuko M, Kikut J, Szczuko U, et al. Nutrition strategy and life style in polycystic ovary syndrome—narrative review. Nutrients 2021; 13(7): 2452.
[http://dx.doi.org/10.3390/nu13072452] [PMID: 34371961]
[28]
Muscogiuri G, Altieri B, de Angelis C, et al. Shedding new light on female fertility: The role of vitamin D. Rev Endocr Metab Disord 2017; 18(3): 273-83.
[http://dx.doi.org/10.1007/s11154-017-9407-2] [PMID: 28102491]
[29]
Begum RF, Singh SA, Mohan S. Impact of junk food on obesity and polycystic ovarian syndrome: Mechanisms and management strategies. Obes Med 2023; 40: 100495.
[http://dx.doi.org/10.1016/j.obmed.2023.100495]
[30]
Kumar R, Minerva S, Shah R, et al. Role of genetic, environmental, and hormonal factors in the progression of PCOS: A review. J Reprod Health Med 2022; 3: 3.
[http://dx.doi.org/10.25259/JRHM_16_2021]
[31]
Khan MJ, Ullah A, Basit S. Genetic basis of polycystic ovary syndrome (PCOS): Current perspectives. Appl Clin Genet 2019; 12: 249-60.
[http://dx.doi.org/10.2147/TACG.S200341]
[32]
Stefanaki C, Pervanidou P, Boschiero D, Chrousos GP. Chronic stress and body composition disorders: Implications for health and disease. Hormones 2018; 17(1): 33-43.
[http://dx.doi.org/10.1007/s42000-018-0023-7] [PMID: 29858868]
[33]
Steegers-Theunissen RPM, Wiegel RE, Jansen PW, Laven JSE, Sinclair KD. Polycystic ovary syndrome: A brain disorder characterized by eating problems originating during puberty and adolescence. Int J Mol Sci 2020; 21(21): 8211.
[http://dx.doi.org/10.3390/ijms21218211] [PMID: 33153014]
[34]
Greenwood EA, Huddleston HG. Insulin resistance in polycystic ovary syndrome: Concept versus cutoff. Fertil Steril 2019; 112(5): 827-8.
[http://dx.doi.org/10.1016/j.fertnstert.2019.08.100] [PMID: 31731944]
[35]
Ibáñez L, Oberfield SE, Witchel S, et al. An international consortium update: Pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr 2017; 88(6): 371-95.
[http://dx.doi.org/10.1159/000479371] [PMID: 29156452]
[36]
Shang Y, Zhou H, Hu M, Feng H. Effect of diet on insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 2020; 105(10): 3346-60.
[http://dx.doi.org/10.1210/clinem/dgaa425] [PMID: 32621748]
[37]
Petrakis D, Vassilopoulou L, Mamoulakis C, et al. Endocrine disruptors leading to obesity and related diseases. Int J Environ Res Public Health 2017; 14(10): 1282.
[http://dx.doi.org/10.3390/ijerph14101282] [PMID: 29064461]
[38]
Purwar A, Nagpure S. Insulin resistance in polycystic ovarian syndrome. Cureus 2022; 14(10): e30351.
[http://dx.doi.org/10.7759/cureus.30351] [PMID: 36407241]
[39]
Escobar-Morreale HF. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14(5): 270-84.
[http://dx.doi.org/10.1038/nrendo.2018.24] [PMID: 29569621]
[40]
Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney L, Teede H. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril 2017; 107(6): 1380-1386.e1.
[http://dx.doi.org/10.1016/j.fertnstert.2017.04.011] [PMID: 28483503]
[41]
Brakta S, Lizneva D, Mykhalchenko K, et al. Perspectives on polycystic ovary syndrome: Is polycystic ovary syndrome research underfunded? J Clin Endocrinol Metab 2017; 102(12): 4421-7.
[http://dx.doi.org/10.1210/jc.2017-01415] [PMID: 29092064]
[42]
Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: A position statement from the european society of endocrinology. Eur J Endocrinol 2014; 171(4): 1-P29.
[http://dx.doi.org/10.1530/EJE-14-0253] [PMID: 24849517]
[43]
Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012; 27(10): 3067-73.
[http://dx.doi.org/10.1093/humrep/des232] [PMID: 22777527]
[44]
Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: A systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod 2016; 31(11): 2619-31.
[http://dx.doi.org/10.1093/humrep/dew243] [PMID: 27907900]
[45]
Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 2013; 28(3): 777-84.
[http://dx.doi.org/10.1093/humrep/des463] [PMID: 23315061]
[46]
Kahn SE. Clinical review 135: The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86(9): 4047-58.
[http://dx.doi.org/10.1210/jcem.86.9.7713] [PMID: 11549624]
[47]
DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005; 83(5): 1454-60.
[http://dx.doi.org/10.1016/j.fertnstert.2004.11.070] [PMID: 15866584]
[48]
Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 2001; 138(1): 38-44.
[http://dx.doi.org/10.1067/mpd.2001.109603] [PMID: 11148510]
[49]
Baillargeon JP, Nestler JE. Commentary: polycystic ovary syndrome: A syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab 2006; 91(1): 22-4.
[http://dx.doi.org/10.1210/jc.2005-1804] [PMID: 16263814]
[50]
Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 2016; 37(5): 467-520.
[http://dx.doi.org/10.1210/er.2015-1104] [PMID: 27459230]
[51]
Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol 2022; 10(9): 668-80.
[http://dx.doi.org/10.1016/S2213-8587(22)00163-2 ] [PMID: 35934017]
[52]
Mizgier M, Jarząbek-Bielecka G, Wendland N, et al. Relation between inflammation, oxidative stress, and macronutrient intakes in normal and excessive body weight adolescent girls with clinical features of polycystic ovary syndrome. Nutrients 2021; 13(3): 896.
[http://dx.doi.org/10.3390/nu13030896] [PMID: 33801995]
[53]
Liu Y, Liu H, Li Z, et al. The release of peripheral immune inflammatory cytokines promote an inflammatory cascade in PCOS patients via altering the follicular microenvironment. Front Immunol 2021; 12: 685724.
[http://dx.doi.org/10.3389/fimmu.2021.685724] [PMID: 34079559]
[54]
Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism 2019; 92: 108-20.
[http://dx.doi.org/10.1016/j.metabol.2018.11.002] [PMID: 30445140]
[55]
Delitala AP, Capobianco G, Delitala G, Cherchi PL, Dessole S. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet 2017; 296(3): 405-19.
[http://dx.doi.org/10.1007/s00404-017-4429-2] [PMID: 28643028]
[56]
Rich-Edwards JW, Spiegelman D, Garland M, et al. Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology 2002; 13(2): 184-90.
[http://dx.doi.org/10.1097/00001648-200203000-00013 ] [PMID: 11880759]
[57]
Bolli A, Bulzomi P, Galluzzo P, Acconcia F, Marino M. Bisphenol A impairs estradiol‐induced protective effects against DLD‐1 colon cancer cell growth. IUBMB Life 2010; 62(9): 684-7.
[http://dx.doi.org/10.1002/iub.370] [PMID: 20836126]
[58]
Geens T, Goeyens L, Covaci A. Are potential sources for human exposure to bisphenol-A overlooked? Int J Hyg Environ Health 2011; 214(5): 339-47.
[http://dx.doi.org/10.1016/j.ijheh.2011.04.005] [PMID: 21570349]
[59]
Koch HM, Calafat AM. Human body burdens of chemicals used in plastic manufacture. Philos Trans R Soc Lond B Biol Sci 2009; 364(1526): 2063-78.
[http://dx.doi.org/10.1098/rstb.2008.0208] [PMID: 19528056]
[60]
Geens T, Aerts D, Berthot C, et al. A review of dietary and non-dietary exposure to bisphenol-A. Food Chem Toxicol 2012; 50(10): 3725-40.
[http://dx.doi.org/10.1016/j.fct.2012.07.059] [PMID: 22889897]
[61]
Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect 2008; 116(1): 39-44.
[http://dx.doi.org/10.1289/ehp.10753] [PMID: 18197297]
[62]
Spanier AJ, Kahn RS, Kunselman AR, et al. Bisphenol a exposure and the development of wheeze and lung function in children through age 5 years. JAMA Pediatr 2014; 168(12): 1131-7.
[http://dx.doi.org/10.1001/jamapediatrics.2014.1397 ] [PMID: 25286153]
[63]
Gascon M, Casas M, Morales E, et al. Prenatal exposure to bisphenol A and phthalates and childhood respiratory tract infections and allergy. J Allergy Clin Immunol 2015; 135(2): 370-378.e7.
[http://dx.doi.org/10.1016/j.jaci.2014.09.030] [PMID: 25445825]
[64]
Schug TT, Janesick A, Blumberg B, Heindel JJ. Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol 2011; 127(3-5): 204-15.
[http://dx.doi.org/10.1016/j.jsbmb.2011.08.007] [PMID: 21899826]
[65]
Rochester JR. Bisphenol A and human health: A review of the literature. Reprod Toxicol 2013; 42: 132-55.
[http://dx.doi.org/10.1016/j.reprotox.2013.08.008] [PMID: 23994667]
[66]
Peretz J, Vrooman L, Ricke WA, et al. Bisphenol a and reproductive health: update of experimental and human evidence, 2007-2013. Environ Health Perspect 2014; 122(8): 775-86.
[http://dx.doi.org/10.1289/ehp.1307728] [PMID: 24896072]
[67]
Tomza-Marciniak A, Stępkowska P, Kuba J, Pilarczyk B. Effect of bisphenol A on reproductive processes: A review of in vitro, in vivo and epidemiological studies. J Appl Toxicol 2018; 38(1): 51-80.
[http://dx.doi.org/10.1002/jat.3480] [PMID: 28608465]
[68]
Caserta D, Di Segni N, Mallozzi M, et al. Bisphenol a and the female reproductive tract: An overview of recent laboratory evidence and epidemiological studies. Reprod Biol Endocrinol 2014; 12(1): 37.
[http://dx.doi.org/10.1186/1477-7827-12-37] [PMID: 24886252]
[69]
Padmanabhan V, Sarma HN, Savabieasfahani M, Steckler TL, Veiga-Lopez A. Developmental reprogramming of reproductive and metabolic dysfunction in sheep: native steroids vs. Environmental steroid receptor modulators. Int J Androl 2010; 33(2): 394-404.
[http://dx.doi.org/10.1111/j.1365-2605.2009.01024.x ] [PMID: 20070410]
[70]
Barontini M, García-Rudaz MC, Veldhuis JD. Mechanisms of hypothalamic-pituitary-gonadal disruption in polycystic ovarian syndrome. Arch Med Res 2001; 32(6): 544-52.
[http://dx.doi.org/10.1016/S0188-4409(01)00325-3 ] [PMID: 11750729]
[71]
Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 2006; 114(6): 597-605.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.621854] [PMID: 16894049]
[72]
Piperi C, Adamopoulos C, Dalagiorgou G, Diamanti-Kandarakis E, Papavassiliou AG. Crosstalk between advanced glycation and endoplasmic reticulum stress: Emerging therapeutic targeting for metabolic diseases. J Clin Endocrinol Metab 2012; 97(7): 2231-42.
[http://dx.doi.org/10.1210/jc.2011-3408] [PMID: 22508704]
[73]
Goldberg T, Cai W, Peppa M, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004; 104(8): 1287-91.
[http://dx.doi.org/10.1016/j.jada.2004.05.214] [PMID: 15281050]
[74]
Tan KCB, Shiu SWM, Wong Y, Tam X. Serum advanced glycation end products (AGEs) are associated with insulin resistance. Diabetes Metab Res Rev 2011; 27(5): 488-92.
[http://dx.doi.org/10.1002/dmrr.1188] [PMID: 21337488]
[75]
Mouanness M, Nava H, Dagher C, Merhi Z. Contribution of advanced glycation end products to PCOS key elements: A narrative review. Nutrients 2022; 14(17): 3578.
[http://dx.doi.org/10.3390/nu14173578] [PMID: 36079834]
[76]
Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56(1): 1-22.
[http://dx.doi.org/10.1210/rp.56.1.1] [PMID: 11237208]
[77]
Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110(6): 911-916.e12.
[http://dx.doi.org/10.1016/j.jada.2010.03.018] [PMID: 20497781]
[78]
Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002; 99(24): 15596-601.
[http://dx.doi.org/10.1073/pnas.242407999] [PMID: 12429856]
[79]
Uribarri J, Cai W, Peppa M, et al. Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007; 62(4): 427-33.
[http://dx.doi.org/10.1093/gerona/62.4.427] [PMID: 17452738]
[80]
González F, Rote NS, Minium J, Kirwan JP. Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91(4): 1508-12.
[http://dx.doi.org/10.1210/jc.2005-2327] [PMID: 16464947]
[81]
Tatone C, Eichenlaub-Ritter U, Amicarelli F. Dicarbonyl stress and glyoxalases in ovarian function. Biochem Soc Trans 2014; 42(2): 433-8.
[http://dx.doi.org/10.1042/BST20140023] [PMID: 24646256]
[82]
Benjamin S, Masai E, Kamimura N, Takahashi K, Anderson RC, Faisal PA. Phthalates impact human health: Epidemiological evidences and plausible mechanism of action. J Hazard Mater 2017; 340: 360-83.
[http://dx.doi.org/10.1016/j.jhazmat.2017.06.036] [PMID: 28800814]
[83]
Jurewicz J, Hanke W. Exposure to phthalates: Reproductive outcome and children health. A review of epidemiological studies. Int J Occup Med Environ Health 2011; 24(2): 115-41.
[http://dx.doi.org/10.2478/s13382-011-0022-2] [PMID: 21594692]
[84]
Neuvonen R, Huovinen M, Dorman DC, Laitinen H, Sahlman H. Phthalates and polycystic ovary syndrome - Systematic literature review. Reprod Toxicol 2023; 121: 108473.
[http://dx.doi.org/10.1016/j.reprotox.2023.108473] [PMID: 37741514]
[85]
Akın L, Kendirci M, Narin F, Kurtoğlu S, Hatipoğlu N, Elmalı F. Endocrine disruptors and polycystic ovary syndrome: Phthalates. J Clin Res Pediatr Endocrinol 2020; 12(4): 393-400.
[http://dx.doi.org/10.4274/jcrpe.galenos.2020.2020.0037 ] [PMID: 32431137]
[86]
Bhattacharya P, Keating AF. Impact of environmental exposures on ovarian function and role of xenobiotic metabolism during ovotoxicity. Toxicol Appl Pharmacol 2012; 261(3): 227-35.
[http://dx.doi.org/10.1016/j.taap.2012.04.009] [PMID: 22531813]
[87]
Craig ZR, Wang W, Flaws JA. Endocrine-disrupting chemicals in ovarian function: Effects on steroidogenesis, metabolism and nuclear receptor signaling. Reproduction 2011; 142(5): 633-46.
[http://dx.doi.org/10.1530/REP-11-0136] [PMID: 21862696]
[88]
Ritter L, Solomon K R, Forget J, Stemeroff M, O’leary C. Persistent organic pollutants an assessment report on: ddt-aldrin-dieldrinendrin-chlordane heptachlor-hexachlorobenzene mirex-toxaphene polychlorinated biphenyls dioxins and furans the international programme on chemical safety (IPCS) within the framework of the inter-organization programme for the sound management of chemicals (IOMC).
[89]
Damstra T. Potential effects of certain persistent organic pollutants and endocrine disrupting chemicals on the health of children. J Toxicol Clin Toxicol 2002; 40(4): 457-65.
[http://dx.doi.org/10.1081/CLT-120006748] [PMID: 12216998]
[90]
Steinemann AC. Fragranced consumer products and undisclosed ingredients. Environ Impact Assess Rev 2009; 29(1): 32-8.
[http://dx.doi.org/10.1016/j.eiar.2008.05.002]
[91]
Nicolopoulou-Stamati P, Hens L, Howard CV, Eds. Endocrine Disrupters. Dordrecht: Springer Netherlands 2001; Vol. 18.
[http://dx.doi.org/10.1007/978-94-015-9769-2]
[92]
Maipas S, Nicolopoulou-Stamati P. Sun lotion chemicals as endocrine disruptors. Hormones 2015; 14(1): 32-46.
[http://dx.doi.org/10.1007/BF03401379] [PMID: 25885102]
[93]
Nicolopoulou-Stamati P, Pitsos MA. The impact of endocrine disrupters on the female reproductive system. Hum Reprod Update 2001; 7(3): 323-30.
[http://dx.doi.org/10.1093/humupd/7.3.323] [PMID: 11392379]
[94]
Prins GS. Endocrine disruptors and prostate cancer risk. Endocr Relat Cancer 2008; 15(3): 649-56.
[http://dx.doi.org/10.1677/ERC-08-0043] [PMID: 18524946]
[95]
Dhir B. Excessive pharmaceutical and personal care products in the environment cause life-threatening diseasesEmerging Contaminants in the Environment. Elsevier 2022; pp. 159-82.
[http://dx.doi.org/10.1016/B978-0-323-85160-2.00014-7]
[96]
Loretz LJ, Api AM, Barraj LM, et al. Exposure data for cosmetic products: lipstick, body lotion, and face cream. Food Chem Toxicol 2005; 43(2): 279-91.
[http://dx.doi.org/10.1016/j.fct.2004.09.016] [PMID: 15621341]
[97]
Lundov MD, Moesby L, Zachariae C, Johansen JD. Contamination versus preservation of cosmetics: A review on legislation, usage, infections, and contact allergy. Contact Dermat 2009; 60(2): 70-8.
[http://dx.doi.org/10.1111/j.1600-0536.2008.01501.x ] [PMID: 19207376]
[98]
Hougeir FG, Kircik L. A review of delivery systems in cosmetics. Dermatol Ther 2012; 25(3): 234-7.
[http://dx.doi.org/10.1111/j.1529-8019.2012.01501.x ] [PMID: 22913440]
[99]
Afonso S, Horita K, Sousa e Silva JP, et al. Photodegradation of avobenzone: Stabilization effect of antioxidants. J Photochem Photobiol B 2014; 140: 36-40.
[http://dx.doi.org/10.1016/j.jphotobiol.2014.07.004 ] [PMID: 25086322]
[100]
Melo LP, Queiroz MEC. Simultaneous analysis of parabens in cosmetic products by stir bar sorptive extraction and liquid chromatography. J Sep Sci 2010; 33(12): 1849-55.
[http://dx.doi.org/10.1002/jssc.201000024] [PMID: 20491059]
[101]
Grandjean P, Clapp R. Perfluorinated alkyl substances. New Solut 2015; 25(2): 147-63.
[http://dx.doi.org/10.1177/1048291115590506] [PMID: 26084549]
[102]
Darbre PD. Aluminium, antiperspirants and breast cancer. J Inorg Biochem 2005; 99(9): 1912-9.
[http://dx.doi.org/10.1016/j.jinorgbio.2005.06.001] [PMID: 16045991]
[103]
Darbre PD. Environmental oestrogens, cosmetics and breast cancer. Best Pract Res Clin Endocrinol Metab 2006; 20(1): 121-43.
[http://dx.doi.org/10.1016/j.beem.2005.09.007] [PMID: 16522524]
[104]
Wolff MS, Teitelbaum SL, McGovern K, et al. Environmental phenols and pubertal development in girls. Environ Int 2015; 84: 174-80.
[http://dx.doi.org/10.1016/j.envint.2015.08.008] [PMID: 26335517]
[105]
Canosa P, Rodríguez I, Rubí E, Cela R. Determination of parabens and triclosan in indoor dust using matrix solid-phase dispersion and gas chromatography with tandem mass spectrometry. Anal Chem 2007; 79(4): 1675-81.
[http://dx.doi.org/10.1021/ac061896e] [PMID: 17297972]
[106]
Allmyr M, Adolfsson-Erici M, McLachlan MS, Sandborgh-Englund G. Triclosan in plasma and milk from Swedish nursing mothers and their exposure via personal care products. Sci Total Environ 2006; 372(1): 87-93.
[http://dx.doi.org/10.1016/j.scitotenv.2006.08.007] [PMID: 17007908]
[107]
Wolf R, Wolf D, Morganti P, Ruocco V. Sunscreens. Clin Dermatol 2001; 19(4): 452-9.
[http://dx.doi.org/10.1016/S0738-081X(01)00190-0 ] [PMID: 11535388]
[108]
Lin SY, Yang YC, Chang CYY, et al. Risk of polycystic ovary syndrome in women exposed to fine air pollutants and acidic gases: A nationwide cohort analysis. Int J Environ Res Public Health 2019; 16(23): 4816.
[http://dx.doi.org/10.3390/ijerph16234816] [PMID: 31801197]

Rights & Permissions Print Cite
Article Metrics
14
2
© 2024 Bentham Science Publishers | Privacy Policy